Contact this trialFirst, we need to learn more about you.
Proteasome Inhibitor
Selinexor + Daratumumab + Carfilzomib + Dexamethasone for Multiple Myeloma
Recruiting1 awardPhase 2
Forest City, North Carolina
This trial is testing the effect of adding selinexor to a regimen of carfilzomib, daratumumab, and dexamethasone for patients with high-risk multiple myeloma that has returned or stopped responding to treatment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.